Repare Therapeutics Inc. (RPTX)
NASDAQ: RPTX · Real-Time Price · USD
1.280
0.00 (0.00%)
Jan 17, 2025, 4:00 PM EST - Market closed
Repare Therapeutics Revenue
Repare Therapeutics had revenue of $66.52M in the twelve months ending September 30, 2024, up 18.19% year-over-year. In the year 2023, Repare Therapeutics had annual revenue of $51.13M, down -61.21%.
Revenue (ttm)
$66.52M
Revenue Growth
+18.19%
P/S Ratio
0.81
Revenue / Employee
$371,642
Employees
179
Market Cap
54.41M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
RPTX News
- 11 days ago - Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions - Business Wire
- 5 weeks ago - Why Is Repare Therapeutics Stock Trading Lower On Friday? - Benzinga
- 5 weeks ago - Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial - Business Wire
- 5 weeks ago - Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial - Business Wire
- 2 months ago - Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib - Business Wire
- 2 months ago - Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results - Business Wire
- 3 months ago - Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial - Business Wire
- 3 months ago - Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor - Business Wire